Investigational drug · Phase 2
Ribaxamase
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "Ribaxamase"
First trial start
2021
Feb 15, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ribaxamase", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant
- Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Ribaxamase" as an intervention, largest first.
- SYN-004 Safety and Tolerability in Allo-HCT SubjectsActive, not recruiting
Theriva Biologics, Inc.Industry
NCT04692181 · 36 participants (planned) · Start Feb 15, 2021 · Primary completion Sep 30, 2029
Drug: SYN-004, Ribaxamase or Placebo · For: Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant; Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics
Sites: St Louis, Missouri
Theriva Biologics, Inc.Industry
NCT02419001 · 11 participants · Start Mar 2015 · Primary completion Sep 2015
Drug: Period 1 - Treatment Sequence AB; Period 1 - Treatment Sequence AC and 2 more · For: Healthy Volunteers
Sites: Columbus, Ohio; Edmonton, Canada; Montreal, Canada
Newest research
PubMed records naming it or its code names, newest first.
- Beta-lactamases in anaerobic, intestinal bacteria: a narrative review.
Dutkiewicz M, Sóki J, Ruppé E · Anaerobe 2026
- How to spare gut microbiota from antibiotic effects? PK-PD based innovative strategies, target specificity, and molecule-to-medicinal properties.
Rai A, Newaskar V, Roy N, et al. · RSC Med Chem 2025
- Fighting against Clostridioides difficile infection: Current medications.
Quan M, Zhang X, Fang Q, et al. · Int J Antimicrob Agents 2024
- How to: prophylactic interventions for prevention of Clostridioides difficile infection.
Reigadas E, van Prehn J, Falcone M, et al. · Clin Microbiol Infect 2021
- Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone.
Kokai-Kun JF, Le C, Trout K, et al. · Infect Drug Resist 2020
- SYN-007, an Orally Administered Beta-Lactamase Enzyme, Protects the Gut Microbiome from Oral Amoxicillin/Clavulanate without Adversely Affecting Antibiotic Systemic Absorption in Dogs.
Connelly S, Fanelli B, Hasan NA, et al. · Microorganisms 2020
Also in development for Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant
- SYN-004Phase 21 trial
Theriva Biologics, Inc. · Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.